Selegiline orally disintegrating tablets (ZELAPAR)

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use

RX page mixes unrelated products: renal import withheld

The retrieved ZELAPAR RX body contains unrelated GAMMAGARD LIQUID overdose/contraindication material. This is a source-integrity problem, not an opposing clinical recommendation.

Before applying: No RX clinical extract from that page is imported in v3.7. Read the exact ZELAPAR DailyMed summary; do not apply any immune-globulin wording to selegiline.

Also check: RX page mixes unrelated products: renal import withheld

Official source

Selegiline orally disintegrating tablets (ZELAPAR)

Product / population: ZELAPAR orally disintegrating selegiline; not EMSAM or conventional capsules.
Renal measure: Creatinine clearance, mL/min.

Renal dosing, restrictions and evidence limits

No renal adjustment is required at CrCl 30-89 mL/min; maintenance at 1.25 mg or 2.5 mg daily depends on clinical response. ZELAPAR is not recommended below CrCl 30 or in end-stage renal disease. This exact-product DailyMed section is used instead of importing clinical text from the RX page, whose retrieved body mixes ZELAPAR with unrelated GAMMAGARD material. Do not transfer these instructions to conventional selegiline capsules or a transdermal product.

Source revision: June 2021 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=380d7717-2a79-42f3-a712-efe5e7696ba0

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Selegiline orally disintegrating tablets (ZELAPAR)

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

ZELAPAR orally disintegrating selegiline; not EMSAM or conventional capsules.

Renal method: Creatinine clearance, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Important v3.7 source / product limitation: Source-quality hold: the ZELAPAR RX page mixed selegiline with unrelated GAMMAGARD material. No RX renal summary is imported from it; the exact-product DailyMed summary is separate.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source quality hold

RX page mixes unrelated products: renal import withheld

The retrieved ZELAPAR RX body contains unrelated GAMMAGARD LIQUID overdose/contraindication material. This is a source-integrity problem, not an opposing clinical recommendation.

How to use this: No RX clinical extract from that page is imported in v3.7. Read the exact ZELAPAR DailyMed summary; do not apply any immune-globulin wording to selegiline.

Selegiline orally disintegrating tablets (ZELAPAR)

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

Selegiline orally disintegrating tablets (ZELAPAR)

ZELAPAR orally disintegrating selegiline; not EMSAM or conventional capsules.

Method: Creatinine clearance, mL/min.

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope Selegiline orally disintegrating tablets (ZELAPAR)

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=380d7717-2a79-42f3-a712-efe5e7696ba0

Exact product and population

ZELAPAR orally disintegrating selegiline; not EMSAM or conventional capsules.

RDM37-SCOPE-selegiline-zelapar-odt · Source section: Selected source product scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

Selegiline orally disintegrating tablets (ZELAPAR)

Open original reference

Open / share this exact local source

DailyMed / Bausch Health US, LLC · ZELAPAR orally disintegrating selegiline; not EMSAM or conventional capsules.

Renal method: Creatinine clearance, mL/min.
Source date: June 2021
Retrieved: 2026-09-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM37-official-selegiline-zelapar-odt-0a13d0fd37-C1 · Source locator: Sections 2.3 and 8.7; Bausch Health US, LLC label.

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=380d7717-2a79-42f3-a712-efe5e7696ba0
Retrieved: 2026-09-07
Exact label title: Selegiline orally disintegrating tablets (ZELAPAR)
DailyMed Set ID: 380d7717-2a79-42f3-a712-efe5e7696ba0
Labeler: Bausch Health US, LLC
Label revision: June 2021
Renal-function method: Creatinine clearance, mL/min.
Source date/version: June 2021
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: a98bb2622f1c34637ef75d9ab28cfdc7e0250811078ac0d3ea659518f81fbdc7

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=380d7717-2a79-42f3-a712-efe5e7696ba0
Source retrieval: 2026-09-07. This is not the source publication or label revision date.
Original source type: source summary
Local text SHA-256: 33a4c47da4fb43d79450a89d49e572ded341e2bacb1922adc88f62f20ff03a31
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report